A third of young men who have sex with men (MSM) who take pre-exposure prophylaxis (PrEP) discontinue it within a six-month period, investigators from the United States report in AIDS and Behavior. Common reasons for stopping included being unable to get an appointment with a doctor and problems with insurance coverage Continue reading

The US Food and Drug Administration (FDA) has approved Gilead's once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to reduce the risk of sexually acquired HIV-1 in at-risk adolescents weighing at least 35kg when used in combination with safe sex practices. When taken consistently, pre-exposure prophylaxis, such as Truvada, can reduce the risk of HIV infection by 92%. Continue reading

  Health Ministry Approves HIV Prevention Drug, but High Price Remains an Obstacle    Continue reading